1. Home
  2. ADVM vs SACH Comparison

ADVM vs SACH Comparison

Compare ADVM & SACH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ADVM
  • SACH
  • Stock Information
  • Founded
  • ADVM 2006
  • SACH 2010
  • Country
  • ADVM United States
  • SACH United States
  • Employees
  • ADVM N/A
  • SACH N/A
  • Industry
  • ADVM Biotechnology: Biological Products (No Diagnostic Substances)
  • SACH Real Estate Investment Trusts
  • Sector
  • ADVM Health Care
  • SACH Real Estate
  • Exchange
  • ADVM Nasdaq
  • SACH Nasdaq
  • Market Cap
  • ADVM 47.4M
  • SACH 46.7M
  • IPO Year
  • ADVM 2014
  • SACH 2017
  • Fundamental
  • Price
  • ADVM $2.17
  • SACH $1.18
  • Analyst Decision
  • ADVM Strong Buy
  • SACH Hold
  • Analyst Count
  • ADVM 5
  • SACH 3
  • Target Price
  • ADVM $23.80
  • SACH $2.25
  • AVG Volume (30 Days)
  • ADVM 339.0K
  • SACH 229.8K
  • Earning Date
  • ADVM 08-11-2025
  • SACH 08-13-2025
  • Dividend Yield
  • ADVM N/A
  • SACH 16.81%
  • EPS Growth
  • ADVM N/A
  • SACH N/A
  • EPS
  • ADVM N/A
  • SACH N/A
  • Revenue
  • ADVM $1,000,000.00
  • SACH N/A
  • Revenue This Year
  • ADVM N/A
  • SACH N/A
  • Revenue Next Year
  • ADVM $18.82
  • SACH $4.52
  • P/E Ratio
  • ADVM N/A
  • SACH N/A
  • Revenue Growth
  • ADVM N/A
  • SACH N/A
  • 52 Week Low
  • ADVM $1.78
  • SACH $0.80
  • 52 Week High
  • ADVM $10.14
  • SACH $3.07
  • Technical
  • Relative Strength Index (RSI)
  • ADVM 44.99
  • SACH 60.46
  • Support Level
  • ADVM $2.27
  • SACH $1.08
  • Resistance Level
  • ADVM $2.60
  • SACH $1.12
  • Average True Range (ATR)
  • ADVM 0.22
  • SACH 0.06
  • MACD
  • ADVM 0.01
  • SACH -0.00
  • Stochastic Oscillator
  • ADVM 22.40
  • SACH 65.91

About ADVM Adverum Biotechnologies Inc.

Adverum Biotechnologies Inc is a clinical-stage company that aims to establish gene therapy as a new standard of care for prevalent ocular diseases. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. Its product candidate, ixoberogene soroparvovec (Ixo-vec), is a single, in-office intravitreal (IVT) injection gene therapy product designed to deliver long-term durable therapeutic levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with bolus anti-vascular endothelial growth factor (VEGF) IVT injections.

About SACH Sachem Capital Corp.

Sachem Capital Corp is a real estate investment trust. The company specializes in originating, underwriting, funding, servicing, and managing a portfolio of short-term loans secured by first mortgage liens on real property located in Connecticut. Its primary objective is to grow the loan portfolio while protecting and preserving capital in a manner that provides for attractive risk-adjusted returns to shareholders over the long term through dividends. The company earns majority of its revenue through Interest income from loans.

Share on Social Networks: